Kamada (KMDA) Aandeel Koers
Kamada Koers
De omzet is de afgelopen 19 jaar met 14,8% per jaar gegroeid tot 180,46 Miljoen USD. De winst per aandeel is de afgelopen 13 jaar met 31,8% per jaar gegroeid. De nettowinstmarge van Kamada ligt op 11,2% en is ten opzichte van -2,2% enkele jaren eerder gestegen. Kamada biedt momenteel een dividendrendement van circa 2,57%. De uitkeringsratio ligt rond 61% van de winst. Analisten hanteren een mediaan koersdoel van 13,00 USD — dat impliceert 67,3% boven de huidige koers. Van de 9 analisten geven 8 het aandeel een koopadvies — per saldo een Kopen-consensus.
Kamada aandeelkoers
Deze data ophalen via de Eulerpool API
100.000 requests/maand gratis · geen creditcard
Kamada bedrijfsmodel & aandelenanalyse
Veelgestelde vragen over Kamada
The business model of Kamada Ltd revolves around the development, production, and commercialization of specialty plasma-derived protein therapeutics. Kamada focuses on three main areas: respiratory diseases, AAT Deficiency, and graft-versus-host disease. By utilizing advanced technologies and expertise in protein purification, Kamada aims to provide innovative solutions for patients and healthcare professionals. With its comprehensive portfolio of FDA-approved products and strategic partnerships, Kamada strives to improve the quality of life for individuals facing these medical conditions. As a leading biopharmaceutical company, Kamada Ltd leverages its extensive knowledge and resources to bring transformative therapies to the market.
Kamada Ltd is primarily active in the biopharmaceutical industry.
The main competitors of Kamada Ltd in the market are companies like Takeda Pharmaceutical Company Limited, CSL Limited, and Grifols, S.A. These companies also operate in the biopharmaceutical industry and offer similar products and services. However, Kamada Ltd distinguishes itself through its innovative research and development efforts, strong global presence, and a diverse product portfolio. Its commitment to technological advancements and strategic partnerships enables Kamada Ltd to stay competitive and maintain a significant market position.
Kamada Ltd is a pharmaceutical company based in Israel. Founded in 1990, the company specializes in the development and production of plasma-derived protein therapeutics. With a focus on rare diseases and respiratory conditions, Kamada's innovative therapies have gained recognition globally. The company has a strong track record of successful partnerships with leading pharmaceutical companies and has expanded its market reach across Europe, the United States, and other regions. Kamada's dedication to research and development has resulted in numerous approvals from regulatory authorities, enhancing its reputation as a leader in the biopharmaceutical industry. Through its commitment to providing life-saving treatments, Kamada Ltd continues to improve the well-being of patients worldwide.
Kamada Ltd has achieved several significant milestones throughout its operation. The company demonstrated its dedication to innovation and development by receiving approval for several therapeutic products. For instance, in 2011, Kamada obtained FDA approval for Glassia, its flagship treatment for Alpha-1 Antitrypsin Deficiency. Additionally, the company successfully launched AATscan, a diagnostic tool used for detecting the presence of Alpha-1 Antitrypsin Deficiency. Furthermore, Kamada established partnerships with renowned global pharmaceutical companies, expanding its market presence and enhancing its research and development capabilities. These accomplishments highlight Kamada Ltd's commitment to advancing medical solutions and solidify their position as a leading player in the healthcare industry.
Kamada Ltd is primarily present in multiple countries and regions worldwide. With a strong global presence, the company operates in various key markets, including the United States, Canada, Europe, Israel, and Latin America. Kamada Ltd's diversified geographical footprint enables it to reach a wide range of customers and expand its distribution network effectively.
Kamada Ltd represents values of innovation, dedication, and excellence. Committed to improving patients' lives, Kamada focuses on developing and commercializing plasma-derived protein therapeutics. With a corporate philosophy centered on integrity, transparency, and ethical conduct, the company aims to deliver high-quality treatments and meet the medical needs of diverse patient populations. By prioritizing research and development initiatives, Kamada strives to leverage its scientific expertise and technological advancements to address unmet medical needs. Through collaboration and partnership, Kamada Ltd is dedicated to making a positive impact in the healthcare industry, promoting patient well-being, and advancing medical advancements.
Analisten hanteren momenteel een gemiddeld koersdoel van 13,00 USD voor het aandeel Kamada (mediaan: 13,00 USD), oftewel +67,3 % ten opzichte van de laatste koers. De consensus is gebaseerd op 9 analistenratings.
9 analisten beoordelen het aandeel Kamada momenteel: 8 adviseren kopen, 1 houden en 0 verkopen. Voor 2026 verwachten analisten dat Kamada een omzet van 202,96 Miljoen USD en winst per aandeel van 0,45 USD behaalt.
Omgezet tegen de huidige wisselkoers noteert het aandeel Kamada op 6,94 EUR (7,77 USD).
Het aandeel Kamada (KMDA) is genoteerd aan 2 beurzen, waaronder: NASDAQ (KMDA).
Kamada Ltd. is a biopharmaceutical company based in Israel that specializes in the development, manufacturing, and marketing of products for the treatment of various diseases. The company's business model is based on its ability to produce innovative products based on proteins that are relevant for the therapy of diseases such as Alpha-1 antit. The company's main areas of focus include the production of intravenous immunoglobulins (IVIG) for the treatment of severe immunodeficiency disorders. IVIG is also used in the treatment of autoimmune diseases such as rheumatoid arthritis and lupus. Kamada is currently the only manufacturer of IVIG in Israel. The company's products are also available in Europe and the USA. Another important area of the company is the production of alpha-1 proteinase inhibitors (AAT) for the treatment of alpha-1 antitrypsin deficiency. This is an inherited disease that can lead to severe lung damage. Kamada has introduced the first AAT product manufactured in Israel to the market. It is also distributed in Europe and the USA. In addition to IVIG and AAT, Kamada also produces Factor VIII concentrates for the treatment of hemophilia and for blood clotting in patients who have received blood transfusions. The company also manufactures enzymes for the diagnosis of diseases and for research. Another business area of the company is the development of biosimilars, which mimic biological medicines that are already on the market. Kamada's biosimilars will help improve access to important therapies and relieve healthcare systems. Currently, the company is developing biosimilars for use in lung diseases and malignant diseases. Kamada's business model also includes collaboration with other companies in the biotechnology industry. The company has partnerships with leading companies such as Baxter, Shire, and Novartis to distribute or co-develop its products. In summary, Kamada's business model is focused on producing and marketing innovative products for the treatment of various diseases. The company specializes in protein production and has partnerships with other biotechnology companies. The different divisions of the company include the production of IVIG, AAT, Factor VIII concentrates, enzymes, and biosimilars. Kamada is also involved in the development of new products to meet patient needs and improve access to important therapies.
De verwachte omzet van Kamada bedraagt 202,96 Miljoen USD. Deze cijfers zijn gebaseerd op huidige financiële gegevens en weerspiegelen de bedrijfsresultaten van het bedrijf.
De verwachte winst van Kamada bedraagt 27,54 Miljoen USD. De nettowinst weerspiegelt de rentabiliteit van het bedrijf na aftrek van alle kosten.
De koers-winstverhouding (P/E) van Kamada bedraagt momenteel 17,40. De P/E-ratio vergelijkt de huidige aandeelkoers met de winst per aandeel en helpt beleggers de waardering van het Kamada-aandeel in te schatten.
De koers-omzetverhouding (P/S) van Kamada bedraagt momenteel 2,36. De P/S-ratio vergelijkt de marktkapitalisatie met de jaarlijkse opbrengsten en dient als waarderingsmaatstaf voor het Kamada-aandeel.
De Eulerpool Kwaliteitsscore voor Kamada is 6/10.
De ISIN van Kamada is IL0010941198. De ISIN (International Securities Identification Number) is een wereldwijd unieke identificatie voor wertpapieren.
De WKN van Kamada is A0JMEX. De WKN (Wertpapierkennnummer) is een zescijferig Duits identificatienummer voor wertpapieren.
Het tickersymbool van Kamada is KMDA. Onder dit beurstickersymbool wordt het Kamada-aandeel op de beurs verhandeld.
Kamada aandeel
Kamada Peer Group
Kamada Ticker
Kamada FIGI
Alle fundamentals en diepgaande analyse van Kamada
Onze aandelenanalyse van het Kamada-aandeel omvat belangrijke financiële kerncijfers zoals de omzet, de winst, de P/E-ratio, de P/S-ratio, de EBIT, evenals informatie over het dividend. Daarnaast bekijken we aspecten zoals aandelen, marktkapitalisatie, schulden, eigen vermogen en verplichtingen van Kamada. Als u meer gedetailleerde informatie zoekt over deze onderwerpen, bieden we op onze subpagina's uitgebreide analyses: